Hôpital Sainte-Thérèse, Montignie sur Sambre, Belgium.
Int J Psychiatry Clin Pract. 2005;9(2):130-7. doi: 10.1080/13651500510018310.
A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation antipsychotics (SGA) for the development of metabolic disorders, especially impaired glucose tolerance, diabetes mellitus and dyslipidemia. The panelists sought to formulate recommendations for practising psychiatrists when initiating and maintaining therapy with SGA, and for the switch of SGA or initiation of further treatment if metabolic complications occur. In addition, recommendations for counselling of the patient and for the cooperation between the psychiatrist and the general physician or diabetologist, respectively, were provided.
一个由来自比利时各大医院的精神科医生、糖尿病专家和药剂师组成的专家组召开了一次研讨会，以审查与第二代抗精神病药物（SGA）相关的最新信息，这些信息涉及代谢紊乱的风险，特别是葡萄糖耐量受损、糖尿病和血脂异常。专家组旨在为开始和维持 SGA 治疗以及在发生代谢并发症时切换 SGA 或开始进一步治疗时，为精神科医生制定建议。此外，还为患者咨询以及精神科医生与普通内科医生或糖尿病专家之间的合作提供了建议。
